Global Conjugate Vaccine Market Insights
Increasing collaborations among key players to develop and introduce vaccines for pneumococcal and meningococcal diseases in the market and ongoing clinical trial studies on pneumococcal vaccines are expected to drive growth of the global conjugated vaccines market in the near future. For instance, in April 2018, Merck & Co, Inc. initiated two Phase III studies of PCV-15 (V114), an investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.
The global conjugate vaccine market was valued at US$ 12,977.2 million in 2018, and is expected to witness a CAGR of 9.6% during the forecast period (2018–2026).
Figure 1. Global Conjugate Vaccine Market value Analysis (US$ Mn), By Product Type
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of various infectious diseases is expected to drive growth of the global conjugate vaccine market
According to World Health Organization (WHO), till November 2017, over 280 million people have been vaccinated with meningococcal A conjugate vaccine in 21 African belt countries. Moreover, increasing prevalence of meningococcal infections is a major factor expected to aid in growth of the global conjugate vaccine market. For instance, according to Centers for Disease Control and Prevention (CDC), in 2015, around 375 total cases of meningococcal disease were reported in the U.S.
Furthermore, development of multivalent conjugate vaccines by key players is expected to drive growth of global conjugate vaccine market. For instance, in September 2018, Pfizer, Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077. The candidate has been developed for the prevention of invasive disease and pneumonia, caused by Streptococcus pneumonia serotypes for adults aged 18 years and older.
Increasing approval for meningococcal conjugate vaccine candidates is expected to boost growth of the global conjugate vaccine market. For instance, in December 2016, Pfizer Inc. received an European Commission (EC) approval for its expanded indication for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine), which is indicated for active immunization against invasive meningococcal disease (IMD), caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.
Global Conjugate vaccine Market- Regional Analysis
North America is expected to witness lucrative growth in the global conjugate vaccine market, owing to increasing prevalence of diseases in the U.S. For instance, according to National Health Interview Survey (NHIS) 2015 reports, risk of pneumococcal disease among adults aged 19-64 years were increased by 2.8% as compared 2014 in the U.S. Moreover, presence of major vaccines manufacturers such as Pfizer Inc. and others in the region is also expected to boost the regional market share during the forecast period
Asia Pacific is also expected to drive growth of the global conjugate vaccine market, owing to increasing initiatives by healthcare provider and hospitals. Moreover, various national governments in the region are focusing on vaccination programs to fulfil the demand. For instance, National Immunization Program by Queensland Government in Australia and Mission Indradhanush vaccination program in India work to provide vaccination among children throughout the respective nations.
Europe is expected to show significant growth rate, owing to rising initiatives by key players in development of conjugate vaccine systems for various purposes. For instance, in March 2015, Pfizer Inc. (U.S.) received the European Commission approval for an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.
Figure 2: Global Conjugate Vaccine Market Value (US$ Mn), By Region (2026)
Source: Coherent Market Insights Analysis (2019)
Global Conjugate Vaccine Market - Competitive Landscape
Key players operating in the global conjugate vaccine market include Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, and Bio-Med
Conjugate vaccine is a combination of a weak antigen with a strong antigen so to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.
Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria.
Increasing cases of infectious diseases such as typhoid, pneumonia, and others is expected to drive the global conjugate vaccine growth. For instance, according to a study published in Science Direct Journal in 2017, 11.9 – 26.9 million cases of typhoid fever occur each year in low- and middle-income countries (LMICs) Moreover, as per the WHO 2016 data, around one million children globally die from pneumonia every year and there has been an increasing demand for safe and effective vaccines that could prevent these deaths.
Healthcare facilities are looking forward to expand their facilities with advanced technologies to create innovative and cost-effective solutions to address barriers to universal vaccination, which in turn contributing to the growth of the global conjugate vaccine market. For instance, on April 25, 2016, innovative smart phones with an app has been provided to various healthcare facilities of northern Mozambique, Africa for 1 year, through the combined partnership of GSK and Vodafone, with funding from GAVI Global Alliance for Vaccines and Immunisation) and USAID (United States Agency for International Development) under mVacciNation pilot program.
This app enables healthcare facilities to report regularly on vaccine stock levels and refrigerator temperatures, improving critical supply chain and cold chain management. Furthermore, it helps health workers to register patients, view their vaccination histories, and also allows to send reminders to registered patients for their next vaccination.
However, there are some challenges in global implementation of protein conjugate polysaccharide vaccines which may hamper the growth of conjugate vaccine market. For instance, according to the NCBI 2014 article, challenges in implementation of conjugate vaccines includes replacement by nonvaccine serotypes, capsule switching, time duration of the antibody protective effect following vaccination, cost of the vaccines, program costs, lack of knowledge of the disease burden, and targeting population groups for vaccination.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 38 market data tables and 33 figures on "Conjugate Vaccine Market” - Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.